Skip to main content
Eurobio Scientific logo

Eurobio Scientific — Investor Relations & Filings

Ticker · ALERS ISIN · FR0013240934 LEI · 969500IQEUEH806GE257 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2023-10-30 Interim / Quarterly Rep…
Country FR France
Listing PA ALERS

About Eurobio Scientific

https://www.eurobio-scientific.com

Eurobio Scientific is an integrated company specializing in in vitro diagnostics (IVD). Its activities cover the entire value chain, from research and development to the manufacturing and commercialization of specialty diagnostic products. The company's core focus areas are transplantation, oncology, and infectious diseases. In transplantation, it provides reagents, software for transplant matching and chimerism monitoring, and culture media for cornea grafts. For oncology, it develops and manufactures prognostic genomic tests for breast and prostate cancer. The group also markets a comprehensive portfolio of molecular tests for detecting infectious diseases, alongside solutions for immunology, fertility, and dermatological conditions.

Recent filings

Filing Released Lang Actions
Eurobio Scientific - Rapport Financier Semestriel au 30 juin 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL' (Half-Year Financial Report) for the period ending June 30, 2023. It contains comprehensive financial statements, including the balance sheet, income statement, cash flow statement, and notes to the financial statements, as well as an audit review report. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2023
2023-10-30 French
Eurobio Scientific: GenDx reduces organ matching time to 3 hours
Regulatory Filings Classification · 100% confidence The document is a press release dated October 17, 2023, announcing the launch of a new product (NGS-Turbo) by the subsidiary GenDx, highlighting technological advancements and strategic partnerships. It includes quotes from management and details about the company's business areas (in vitro diagnostics, HLA typing). This type of announcement, focusing on a specific operational or product development milestone rather than comprehensive financial results (like 10-K or ER) or management changes (MANG), is best classified as a general announcement. Since it doesn't fit the specific categories like DIV, CAP, or DIRS, and it is not a formal regulatory filing like a 10-K or a report itself, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for significant, non-standard corporate news releases that are often filed with regulators.
2023-10-17 English
Eurobio Scientific : GenDx réduit à 3h la durée des tests de compatibilité d’organes
Regulatory Filings Classification · 100% confidence The document is a press release dated October 17, 2023, announcing the launch of a new product (NGS-Turbo) by Eurobio Scientific's subsidiary, GenDx, in partnership with Oxford Nanopore Technologies. It details the product's benefits (speed in organ compatibility testing) and includes quotes from management. It also provides a 'Prochain rendez-vous financier' (Next financial appointment) for the annual revenue release on January 30, 2024. This content structure—a news announcement about a product launch, strategic development, and future reporting dates—is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (like 10-K or IR) but an announcement of operational news and product milestones, and it is not explicitly a proxy statement (DEF 14A) or a management discussion (MDA), the most fitting category for a significant operational/product announcement that is not a formal earnings report is the Earnings Release (ER) category, as these often accompany or precede formal earnings announcements, or the Regulatory Filings (RNS) as a general announcement. Given the focus on a major product launch and strategic update, it functions similarly to an ER highlighting operational success, but since it's not explicitly stating Q3/Q4 results, it leans towards a general corporate announcement. However, in the context of financial reporting, major operational news releases often fall under ER if they are timely, or RNS if they are purely informational. Since it is a detailed announcement of a significant business event, and not a short notice of a report publication, I will classify it as an Earnings Release (ER) as it communicates key performance drivers and future outlook, even if it's not the formal earnings number release itself. If ER is too specific, RNS is the fallback. Given the context of financial reporting databases, product launches that drive future revenue are often grouped near ERs. I will select ER as the primary classification for a significant operational announcement.
2023-10-17 French
Eurobio Scientific : Results for the First Half of 2023
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive report detailing the financial performance of Eurobio Scientific for the first half of 2023. It includes detailed financial tables (income statement, balance sheet data), management's analysis of business trends, EBITDA margins, and strategic outlook. It is not a mere announcement of a report, as it contains the substantive financial data itself. Therefore, it is classified as an Interim/Quarterly Report. H1 2023
2023-10-11 English
EUROBIO SCIENTIFIC : RESULTATS DU 1ER SEMESTRE 2023
Earnings Release Classification · 100% confidence The document is titled "RESULTATS DU 1ER SEMESTRE 2023" (First Half 2023 Results) and presents detailed consolidated financial figures (Income Statement, Balance Sheet items) for the six months ended June 30, 2023. It discusses key performance indicators like revenue growth, EBITDA margin, and cash flow. This content structure is characteristic of a comprehensive financial report covering a period shorter than a full year. The document explicitly states the results are for the period ending June 30, 2023, which points directly to an Interim/Quarterly Report. It is not merely an announcement of a report (RPA) as the full results and analysis are present, and the length is substantial (over 12,000 characters). Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2023
2023-10-11 French
EUROBIO : ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF 2023
Earnings Release Classification · 100% confidence The document explicitly states it presents the "consolidated half-year revenues for the period ending June 30, 2023," and uses terms like "H1 2023" and "half-year core business revenues." This content structure, focusing on detailed financial performance for a period shorter than a full year (six months), aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K), nor is it just a brief Earnings Release (ER) as it contains detailed tables and strategic commentary typical of a comprehensive interim filing. The document length (5898 chars) suggests it is the report itself, not just an announcement of the report. H2 2023
2023-07-24 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.